SRx Health Solutions (SRXH) Q4 2024 earnings summary

Executive summary

• Achieved strong performance in 2024, executing a turnaround strategy focused on profitability and sustainable growth, with Q4 revenue up 26% year-over-year to $7.2 million, driven by 32% growth on Amazon and Chewy and expansion into Chewy Canada.

• Strategic exit from non-core and unprofitable channels led to a 9% decline in annual net revenues, but digital platform revenues increased 8% year-over-year.

• Gross margin expanded to 36% in Q4, up 2,705 basis points year-over-year, with four consecutive quarters of improvement.

• Signed agreements to sell Halo Asia for $8.1 million and established new royalty streams, with plans to distribute up to 55% of annual royalties to shareholders.

• Net loss improved 99% year-over-year to $(0.2) million for the full year and 90% in Q4 to $(1.6) million; loss per share improved to $(0.10) for the year and $(0.50) in Q4.

Financial highlights

• Full-year gross profit margin rose to 37%, up 657 basis points year-over-year; Q4 gross margin at 36%.

• Adjusted EBITDA loss improved 78% year-over-year to $1.9 million for the full year and 80% in Q4 to $700,000.

• GAAP net loss nearly break-even at $168,000 for the year, a 99% improvement from $23 million net loss in 2023.

• SG&A reduced by 22% year-over-year.

• $6.2 million gain from extinguishing debt and accounts payable, strengthening the balance sheet.

Outlook and guidance

• Management expresses confidence in achieving profitability through operational leverage in 2025, citing sustained gross margin expansion and net loss improvement.

• Expect continued top-line momentum and increased emphasis on e-commerce platforms through 2025 and beyond.

• Confident in ability to drive long-term profitable growth and further explore shareholder value opportunities.

• Positioned to capitalize on emerging markets in pet health and specialty healthcare segments.